ES2063200T3 - Conjugados proteicos magneticos, procedimiento para su preparacion y su empleo. - Google Patents

Conjugados proteicos magneticos, procedimiento para su preparacion y su empleo.

Info

Publication number
ES2063200T3
ES2063200T3 ES90111264T ES90111264T ES2063200T3 ES 2063200 T3 ES2063200 T3 ES 2063200T3 ES 90111264 T ES90111264 T ES 90111264T ES 90111264 T ES90111264 T ES 90111264T ES 2063200 T3 ES2063200 T3 ES 2063200T3
Authority
ES
Spain
Prior art keywords
preparation
protein conjugates
procedure
cells
magnetic protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90111264T
Other languages
English (en)
Inventor
Peter Dr Hermentin
Reiner Donges
Udo Dr Franssen
Karlheinz Dr Enssle
Heinz-Jurgen Dr Friesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Application granted granted Critical
Publication of ES2063200T3 publication Critical patent/ES2063200T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/20—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations containing free radicals, e.g. trityl radical for overhauser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/90—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids characterised by small molecule linker used to couple immunoreagents to magnetic particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CONJUGADOS DE PROTEINA MAGNETICOS CON FORMULA (I) (FORMULA) EN LA QUE N = 1 A 6, CON PREFERENCIA N = 1 O 2, SIENDO M MATERIALES O PARTICULAS DISPERSABLES, QUE REACCIONA MAGNETICAMENTE, CON GRUPOS AMINO Y P UNA PROTEINA. PROCEDIMIENTO DE FABRICACION Y APLICACIONES PARA LA ELIMINACION DE CELULAS O ANTIGENES, RECEPTORES, SUBSTRATOS, ETC DE SOLUCIONMES ACUOSAS SALINAS.
ES90111264T 1989-06-19 1990-06-14 Conjugados proteicos magneticos, procedimiento para su preparacion y su empleo. Expired - Lifetime ES2063200T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3919873A DE3919873A1 (de) 1989-06-19 1989-06-19 Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung

Publications (1)

Publication Number Publication Date
ES2063200T3 true ES2063200T3 (es) 1995-01-01

Family

ID=6382977

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90111264T Expired - Lifetime ES2063200T3 (es) 1989-06-19 1990-06-14 Conjugados proteicos magneticos, procedimiento para su preparacion y su empleo.

Country Status (12)

Country Link
US (1) US5095097A (es)
EP (1) EP0403961B1 (es)
JP (1) JP2858883B2 (es)
KR (1) KR0154120B1 (es)
AT (1) ATE102052T1 (es)
AU (1) AU639867B2 (es)
CA (1) CA2019218C (es)
DE (2) DE3919873A1 (es)
DK (1) DK0403961T3 (es)
ES (1) ES2063200T3 (es)
IE (1) IE63666B1 (es)
PT (1) PT94398B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007138A1 (en) 1992-09-14 1994-03-31 Fodstad Oystein Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
NO180658C (no) * 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5585278A (en) * 1994-10-27 1996-12-17 Bayer Corporation Method for coupling antibody to novel latex substrate and its use in immunoassay
EP0814849A1 (en) * 1995-10-19 1998-01-07 BRACCO International B.V. Magnetically labeled chemoattractants as targeted contrast agents in the nmr imaging of living tissues
NO961031D0 (no) 1996-03-13 1996-03-13 Det Norske Radiumshospital Tum Fremgangsmåte til å drepe uönskede målceller
JP4127724B2 (ja) * 1996-03-26 2008-07-30 サイレックス インコーポレーテッド リンパ球機能の測定方法
JP3662347B2 (ja) * 1996-06-10 2005-06-22 日鉄鉱業株式会社 医療用粉体
US6379975B1 (en) * 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
US7169571B2 (en) 1997-09-12 2007-01-30 Cylex, Inc. Methods for measurement of lymphocyte function
US6828157B1 (en) 1999-05-04 2004-12-07 Dan A. Pankowsky Products and methods for single parameter and multiparameter phenotyping of cells
WO2000067021A1 (en) * 1999-05-04 2000-11-09 Pankowsky Dan A Products and methods for single parameter and multiparameter phenotyping of cells
US6682940B2 (en) 1999-05-04 2004-01-27 Dan A. Pankowsky Products and methods for single parameter and multiparameter phenotyping of cells
US20020150952A1 (en) * 2001-04-17 2002-10-17 Peter Sottong Methods for measuring lymphocyte activation by mitogens and antigens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2334106A1 (fr) * 1975-12-02 1977-07-01 Pasteur Institut Gel magnetique convenant pour dosages immunoenzymatiques
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
NO155316C (no) 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US4554088A (en) 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US4698302A (en) * 1983-05-12 1987-10-06 Advanced Magnetics, Inc. Enzymatic reactions using magnetic particles
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4814098A (en) * 1986-09-06 1989-03-21 Bellex Corporation Magnetic material-physiologically active substance conjugate

Also Published As

Publication number Publication date
JP2858883B2 (ja) 1999-02-17
EP0403961B1 (de) 1994-03-02
DK0403961T3 (da) 1994-06-27
IE902194L (en) 1990-12-19
US5095097A (en) 1992-03-10
AU639867B2 (en) 1993-08-05
PT94398A (pt) 1991-02-08
PT94398B (pt) 1997-01-31
ATE102052T1 (de) 1994-03-15
CA2019218A1 (en) 1990-12-19
JPH03184999A (ja) 1991-08-12
IE902194A1 (en) 1991-01-02
DE59004731D1 (de) 1994-04-07
CA2019218C (en) 2001-01-02
EP0403961A3 (de) 1991-07-17
IE63666B1 (en) 1995-05-31
DE3919873A1 (de) 1990-12-20
AU5717890A (en) 1990-12-20
EP0403961A2 (de) 1990-12-27
KR910000797A (ko) 1991-01-30
KR0154120B1 (ko) 1998-10-15

Similar Documents

Publication Publication Date Title
ES2063200T3 (es) Conjugados proteicos magneticos, procedimiento para su preparacion y su empleo.
DK0458878T3 (da) Nyt monoklonalt antistof mod et nyt antigen, der er associeret med humane tumorer
ATE108022T1 (de) Synthetische peptide und deren verwendung zur diagnose und impfung für aids und arc.
EP0224934A3 (en) Contrast agent, process for its preparation and its use for ultrasonic imaging
ES8701497A1 (es) Un metodo para preparar un complejo inmunogeno
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
PT84370B (pt) Processo para a producao de anticorpos monoclonais e antigenios contra o carcinoma do pulmao humano do tipo celulas grandes e alguns outros carcinomas humanos
IE902195L (en) Magnetic protein conjugates
ES2064373T3 (es) Conjugados de proteinas magneticos, procedimiento para su preparacion y su empleo.
FR2601679B1 (fr) Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
SE8900899L (sv) Peptider foer diagnostisk anvaendning
DK292584A (da) Biologisk aktive konjugater, deres fremstilling og anvendelse
DE3854096D1 (de) Verfahren zur Isolierung von Basalmembranproteinen aus menschlichen und tierischen Geweben.
GB8906708D0 (en) Improvements relating to the radiolabelling of proteins
FR2559157B1 (fr) Nouvel hexapeptide, son procede d'obtention et les compositions pharmaceutiques qui le contiennent
SE8500340D0 (sv) Antikroppspreparation samt sett att framstella och sett att anvenda densamma
RO85246A3 (ro) Procedeu de preparare a antigenului citomecanic uman
ES2002532A6 (es) Procedimiento para la preparacion de un complejo inmunogenico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 403961

Country of ref document: ES